An exploratory study to investigate the pharmacokinetics and effects of DABIgatran etexilate in patients with stable severe RENAL disease: DabiRenal

Trial Profile

An exploratory study to investigate the pharmacokinetics and effects of DABIgatran etexilate in patients with stable severe RENAL disease: DabiRenal

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2015

At a glance

  • Drugs Dabigatran etexilate (Primary)
  • Indications Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
  • Focus Pharmacokinetics
  • Acronyms DABIRENAL
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 30 Jan 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
    • 30 Oct 2013 Planned end date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 22 Oct 2012 Planned End Date changed from 18 Apr 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top